ANIMATION

Apoptosis and BCL-2

Share this article with:

ABT-199/GDC-0199 is a small molecule drug in co-development by Abbvie and Genentech for the selective inhibition of BCL-2, a key regulator of cellular apoptosis. BCL-2, part of the larger BCL-2 family, is responsible for the sequestration of pro-apoptopic proteins along the mitochondrial membrane. Displacement of these proteins from BCL-2 in cancerous cells may prime these cells for apoptosis.

Share It:
Contact XVIVO

Client


Abbvie; Genentech

DARPA was very pleased with the Trauma Pod of the Future video. It was instrumental in presenting this futuristic and complex research program and provided an insight to the audience and reviewers that they would not have otherwise achieved. The quality of the work is exceptional and the video has been shown hundreds of times with great success; it is one of the most popular videos that I have used in my presentations.

Richard Satava, MD, Program Manager, Advanced Biomedical Technologies Program, DARPA